Rui-hua Xu, MD, PhD
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer (NCT06700603) | Rui-hua Xu, MD, PhD | 2024-11-20 |
| Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC (NCT06501664) | Rui-hua Xu, MD, PhD | 2024-08-01 |
| A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (NCT06487702) | Rui-hua Xu, MD, PhD | 2024-07-10 |
| A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD (NCT06329947) | Rui-hua Xu, MD, PhD | 2024-05-22 |
Track Rui-hua Xu, MD, PhD automatically
Every clearance here is in the API, with alerts when new ones post.